• In early May 2026, Mineralys Therapeutics reported that it had submitted a New Drug Application for its aldosterone synthase inhibitor lorundrostat in treatment-resistant hypertension, scheduled its first-quarter 2026 results and earnings call for May 6, and granted inducement equity awards to new non-executive employees under its 2025 inducement plan.
• Alongside this regulatory progress, Mineralys is drawing increased investor and industry attention through positive commentary on lorundrostat’s clinical profile and planned participation in the Bank of America Securities 2026 Health Care Conference, highlighting the drug’s potential role in an underserved hypertension market.
• Against this backdrop of NDA progress and upcoming conference visibility for lorundrostat, we’ll now examine how these developments shape Mineralys’ investment narrative.

The latest GPUs need a type of rare earth metal called Terbium and there are only 31 companies in the world exploring or producing it. Find the list for free.

Mineralys Therapeutics Investment Narrative Recap

To own Mineralys, you have to believe lorundrostat can convert the company from a single‑asset, loss‑making biotech into a commercial hypertension player, while clearing the FDA review. The recent NDA progress and conference exposure are supportive signals, but they do not materially change the near term catalyst, which remains the December 22, 2026 PDUFA decision, or the key risk that ongoing net losses and cash burn persist without timely product revenue.

The most relevant new item here is Mineralys’ planned participation in the Bank of America Securities 2026 Health Care Conference, where management will spotlight lorundrostat’s NDA status and hypertension data. For investors, this event sits alongside the Q1 2026 results as a way to track how the company frames its commercial plans, spending and cash runway against the upcoming PDUFA decision, all of which tie back into the core risk of extended losses if uptake lags.

Yet while lorundrostat’s profile is attracting attention, investors should also be aware that Mineralys remains a single‑asset story and that...

Mineralys Therapeutics’ narrative projects $215.7 million revenue and $23.5 million earnings by 2029. This implies an earnings increase of about $195 million from -$171.4 million today.

Uncover how Mineralys Therapeutics' forecasts yield a $50.88 fair value, a 69% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were, even before this news, projecting about US$388 million of revenue by 2029, which is far more upbeat than consensus on how quickly lorundrostat could scale, so this kind of outlook may shift meaningfully as investors weigh fresh NDA progress alongside the risk that a single regulatory setback could still undermine that entire revenue story.

Explore 4 other fair value estimates on Mineralys Therapeutics - why the stock might be worth just $49.38!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Mineralys Therapeutics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Mineralys Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mineralys Therapeutics' overall financial health at a glance.

Looking For Alternative Opportunities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• Find 44 companies with promising cash flow potential yet trading below their fair value.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.